<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05041673</url>
  </required_header>
  <id_info>
    <org_study_id>0304932</org_study_id>
    <nct_id>NCT05041673</nct_id>
  </id_info>
  <brief_title>Anti-diabetic Drugs and Fatty Liver Management</brief_title>
  <official_title>Efficacy of Vildagliptin, Liraglutide and Empagliflozin in the Management of Fatty Liver Disease Among Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eva Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 DM is one of the major risk factors for development of non-alcoholic fatty liver&#xD;
      disease. The pooled prevalence of fatty liver among diabetics is 54% (95% CI 45%-64%). Until&#xD;
      now there is no well-established treatment for fatty liver disease.&#xD;
&#xD;
      Study setting: Randomized controlled trial&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Patients with type 2 DM plus Fatty Liver.&#xD;
&#xD;
      Arms and Interventions&#xD;
&#xD;
      1. Experimental arms: Group 1: metformin +/- insulin +/- sulfonylurea Group 2: Metformin plus&#xD;
      vildagliptin+/- insulin +/- sulfonylurea Group 3: Metformin plus liraglutide+/- insulin+/-&#xD;
      sulfonylurea Group 4: Metformin plus empagliflozin +/- insulin +/- sulfonylurea&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rational: Type 2 DM is one of the major risk factors for development of non-alcoholic fatty&#xD;
      liver disease. The pooled prevalence of fatty liver among diabetics is 54% (95% CI 45%-64%).&#xD;
      Until now there is no well-established treatment for fatty liver disease.&#xD;
&#xD;
      Study setting: Randomized controlled trial&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Patients with type 2 DM plus Fatty Liver.&#xD;
&#xD;
      NAFLD diagnostic criteria:&#xD;
&#xD;
        -  Fatty Liver Index (FLI) 60 or more plus Ultrasound features of fatty liver.&#xD;
&#xD;
           - Inclusion criteria&#xD;
&#xD;
             1. Age above 18. 2- HbA1C less than 10.&#xD;
&#xD;
                Sample size: Based on the result reported by Armstrong et al, the proportion of&#xD;
                patients on standard care who showed resolution of steatosis versus intervention&#xD;
                group on liraglutide was 9% vs 39%, using power of 80%, precision of 5%, the&#xD;
                minimal required sample size was 24 for each group and we increased it to 30 to&#xD;
                compensate for drop-out. So, 120 subjects will be divided into 4 equal groups.&#xD;
&#xD;
                Study Design: Interventional (Randomized Clinical Trial) Allocation: Randomized&#xD;
                Intervention Model: Parallel Assignment Masking: No masking. Study duration: 12&#xD;
                months of follow up&#xD;
&#xD;
                Data collection methods and tools&#xD;
&#xD;
             1. Filling the pre-designed structured interview questionnaire from patients that&#xD;
                includes:&#xD;
&#xD;
                  -  Demographic traits: age, sex, marital status, education, occupation and&#xD;
                     residency.&#xD;
&#xD;
                  -  Habits: smoking, physical exercise, dietary habits, drug use.&#xD;
&#xD;
                  -  Social history, focusing on smoking status, occupation, presence of children&#xD;
                     at home and plans for future pregnancy (as appropriate).&#xD;
&#xD;
                  -  Drug history&#xD;
&#xD;
             2. Clinical data about:&#xD;
&#xD;
                  -  Present/ past/ family history on thyroid diseases, and autoimmune disease.&#xD;
&#xD;
                  -  Comorbidities: hypertension, coronary heart disease, chronic obstructive air&#xD;
                     way disease (COPD), obesity and others.&#xD;
&#xD;
                  -  Medications used: dose, frequency and route of administration.&#xD;
&#xD;
                  -  Hospitalization.&#xD;
&#xD;
                  -  Body measures: weight, height, body mass index (BMI), waist circumference.&#xD;
&#xD;
                  -  Vital signs: pulse, blood pressure, heart rate.&#xD;
&#xD;
                  -  The compliance was ascertained through direct questioning at each clinic&#xD;
                     visits and by inspecting her pill bottles.&#xD;
&#xD;
                  -  Patient satisfaction and quality of life will be measured at baseline and at&#xD;
                     the end of Intervention.&#xD;
&#xD;
             3. Investigations&#xD;
&#xD;
                  -  Lab: HCV Ab, HBsAg, HBcAb, ALT, AST, GGT, FBS, HBA1c, PPBS, Fasting insulin,&#xD;
                     CBC, Cholesterol, LDL, HDL, TGs, uric acid.&#xD;
&#xD;
                  -  Calculation of the following score FLI, NAFLD-LFS, FIB-4, NFS.&#xD;
&#xD;
                  -  Imaging: ultrasound/FIBROSCAN/ MRI.&#xD;
&#xD;
                  -  Adverse effects of the drugs were systematically identified by careful health&#xD;
                     interview and clinical examinations. T-Bil, AST, ALT, and hematological values&#xD;
                     were measured for evaluation at every outpatient clinic visit.&#xD;
&#xD;
                Follow-up&#xD;
&#xD;
                All patients were followed up for twelve months:&#xD;
&#xD;
        -  Dietary follow up.&#xD;
&#xD;
        -  Liver enzymes (ALT, AST and GGT) at least every 3 months and more if clinically&#xD;
           indicated&#xD;
&#xD;
        -  Scores follow up: NFS and FIB-4 every 3 months.&#xD;
&#xD;
        -  Fibroscan at end of 1-year follow up.&#xD;
&#xD;
        -  MRI at end of 1-year follow up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">September 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 22, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in steatosis as measured using CAP score (fibroscan) and MRI</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in liver enzymes</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fibrosis grade</measure>
    <time_frame>12 months</time_frame>
    <description>as measured by transient elastography (Fibroscan)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Fatty Liver, Nonalcoholic</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin +/- insulin +/- sulfonylurea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin plus vildagliptin +/- insulin +/- sulfonylurea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin plus liraglutide +/- insulin+/- sulfonylurea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin plus empagliflozin +/- insulin +/- sulfonylurea</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Antidiabetic drugs</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Liraglutide</other_name>
    <other_name>empagliflozin</other_name>
    <other_name>Vildagliptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 DM with fatty liver disease.&#xD;
&#xD;
          -  HbA1C less than 10.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Alcohol intake.&#xD;
&#xD;
          2. BMI 40 or more.&#xD;
&#xD;
          3. CKD with e GFR less than 60.&#xD;
&#xD;
          4. chronic liver diseases (chronic viral hepatitis, autoimmune hepatitis, Wilson's&#xD;
             disease, hemochromatosis, alfa-1 antitrypsin deficiency)&#xD;
&#xD;
          5. Atherosclerotic cardiovascular disease.&#xD;
&#xD;
          6. Celiac disease.&#xD;
&#xD;
          7. Clinically evident liver cirrhosis.&#xD;
&#xD;
          8. Patients who have ever had medullary thyroid carcinoma (MTC) or who have a family&#xD;
             member who has ever had and patients who have multiple endocrine neoplasia syndrome&#xD;
             type 2 (MEN 2)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alexandria University.</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Kamal</last_name>
      <phone>01279734654</phone>
      <email>Ahmed.Kamal@alexmed.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Noha Amin</last_name>
      <phone>01003999287</phone>
      <email>nohaamin8@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Ahmed Kamal</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

